Core Viewpoint - The recent controversy involving Huaxi Biological and brokerage reports highlights the need for improved interaction and accountability between listed companies and brokerage research teams, suggesting a potential shift in the dynamics of this relationship [6][8]. Group 1: Company Actions and Statements - Huaxi Biological issued a follow-up statement on May 21, further explaining its concerns regarding brokerage reports published on May 17, specifically addressing misleading conclusions about the medical aesthetics industry [4][5]. - The company pointed out that certain brokerage reports claimed that collagen products outperform hyaluronic acid without any supporting public data or scientific research [4][6]. - Huaxi Biological emphasized that its intention in naming the brokerages was not to attack them but to encourage a more informed and collaborative approach to industry analysis [5][6]. Group 2: Industry Implications - The incident has prompted discussions about redefining the interaction between listed companies and brokerage research, potentially leading to a more rigorous review process for research reports [8][9]. - Analysts suggest that this situation serves as a warning for brokerages to enhance the professionalism and accuracy of their reports, as previous instances of regulatory scrutiny have already highlighted issues within the industry [9][10]. - The ongoing scrutiny of brokerage reports may lead to a more cautious approach in the future, with an emphasis on compliance and thorough validation of research findings [10][11].

Core Viewpoint - The article discusses the ongoing conflict between Huaxi Biological and several securities firms regarding the market perception of hyaluronic acid versus collagen protein, highlighting Huaxi's efforts to defend its core business amidst declining performance and market competition [1][10]. Company Performance - Huaxi Biological started with hyaluronic acid and currently holds nearly 50% of the global market share, expanding into downstream medical products, functional skincare, and functional foods [4][5]. - Despite the pandemic, Huaxi maintained positive revenue and profit growth until 2021, with a peak market value exceeding 140 billion yuan [5][7]. - From 2022 to 2024, Huaxi's net profit is projected to decline from 9.71 billion yuan to 1.74 billion yuan, with its market value dropping from over 140 billion yuan to 25.3 billion yuan [7]. Market Comparison - In contrast, collagen protein companies like Juzhi Biological and Jinbo Biological have seen significant growth, with Juzhi's net profit increasing from 1 billion yuan in 2022 to 20.62 billion yuan in 2024, and Jinbo's from 1.09 billion yuan to 7.31 billion yuan, reflecting compound annual growth rates of 43.45% and 158.97%, respectively [8]. - Both companies have achieved new stock price highs, with market values of 87.5 billion HKD and 51.1 billion yuan [8]. Industry Dynamics - The article emphasizes that both hyaluronic acid and collagen are essential components that decrease with age, suggesting that both can positively impact skin health [10][12]. - There is currently no official data to determine which component is superior, but the market's shift towards collagen indicates a growing consumer preference for new ingredients [11][12]. - Huaxi's recent acquisition of a stake in a collagen company and the introduction of collagen products indicate its recognition of the market trend, although its current revenue from collagen remains unspecified [13][14]. Future Outlook - The article suggests that regardless of the outcome of the ongoing dispute, Huaxi may continue to face challenges in growing its hyaluronic acid sales while struggling to establish its collagen product line [14].

Core Viewpoint - The article discusses the rise of Fan Daidi and Yan Jianya, founders of Juzhi Biotechnology, who recently became the richest couple in Shaanxi with a stock value exceeding 45 billion yuan, highlighting their journey from academia to entrepreneurship and the challenges they faced in commercializing their scientific research [2][19]. Group 1: Background and Early Career - Fan Daidi, born in 1966, comes from an ordinary family in Weinan, Shaanxi, and became China's first female PhD in biochemical engineering after studying at Northwest University and East China University of Science and Technology [3]. - After a research visit to MIT in 2000, Fan returned to lead a team at Northwest University to develop human-derived collagen, marking the beginning of her entrepreneurial journey [4]. Group 2: Formation of Juzhi Biotechnology - In 2000, Yan Jianya left academia to co-found Juzhi Biotechnology with Fan, combining her technical expertise with his entrepreneurial spirit [5]. - The couple faced significant challenges in the early years, relying on personal savings to fund the company as they struggled to transition from small-scale to industrial production [6]. Group 3: Business Development and Growth - Yan Jianya's strategic move to enter the military industry in 2003 helped alleviate financial pressures and opened doors for mixed-ownership enterprises [7][8]. - By 2009, Juzhi Biotechnology began to gain traction, launching its first commercial brand, Keli Jin, and forming partnerships that significantly increased its market presence [9][10]. Group 4: Financial Performance and Market Position - Juzhi Biotechnology reported revenues exceeding 3.7 billion yuan in the last three years, with a gross margin of 87.2% [15]. - The company’s IPO valuation exceeded 19.3 billion yuan, attracting investments from notable firms, indicating strong market confidence [16][17]. Group 5: Recent Developments and Challenges - In 2022, Juzhi Biotechnology became the first Hong Kong-listed company in the collagen industry, with revenues projected to grow from 9.57 billion yuan in 2019 to 55.38 billion yuan by 2024, reflecting a compound annual growth rate of 42% [18]. - However, the company faces challenges such as high sales expenses, reliance on a single brand, and governance issues following the transition of leadership to the next generation [19][20].

Group 1 - Ping An Health Medical Technology Co., Ltd. has entered into a strategic cooperation with Shenzhen Gaohe Pharmaceutical Trading Co., Ltd. regarding the Kefu Mei brand, marking a new phase in its strategic layout in the medical health equipment sector [1][3] - The collaboration aims to innovate the application of recombinant collagen and related products, providing users with rich, convenient, intelligent, and more efficient health management solutions [1][3] - Ping An Health has established itself as a leading provider of medical health and elderly care management services in China, leveraging its extensive resources and service networks [3][4] Group 2 - Kefu Mei, a core brand under Juzhi Biotechnology, has focused on recombinant collagen since its establishment in 2011, addressing skin issues such as sensitivity, dermatitis, acne, and post-beauty care [3] - Gaohe Pharmaceutical, as the national general distributor for Kefu Mei retail pharmacy channels, has gained significant market recognition through four years of operation [3][4] - The partnership will explore innovative applications of recombinant collagen in health management, disease prevention, and medical rehabilitation, aiming to provide more precise and efficient solutions for users [3][4] Group 3 - The collaboration is seen as a significant milestone in Ping An Health's brand strategy for medical equipment, integrating Gaohe Pharmaceutical's terminal capabilities, Kefu Mei's technological advantages, and Ping An Health's resource platform [4] - Both companies express their commitment to enhancing consumer health solutions and contributing to the improvement of public health levels [4]

Core Viewpoint - Huaxi Biological criticized ten research reports from nine brokerages, claiming they misled the market by promoting a "hyaluronic acid obsolescence theory" in favor of recombinant collagen products [2][3][5] Group 1: Research Reports Criticism - Huaxi Biological specifically named four reports from brokerages including Huatai Securities and Anxin Securities, which emphasized the advantages of recombinant collagen over hyaluronic acid in terms of efficacy and safety [3][5] - The reports in question did not explicitly use the term "obsolete" but suggested that collagen had superior applications in certain scenarios [5] - Huaxi Biological's article indicated that the emergence of the "hyaluronic acid obsolescence" narrative was driven by "restless capital" seeking new investment themes [3][9] Group 2: Timeline and Context - The criticism of the research reports is rooted in a timeline starting from 2022, when the recombinant collagen concept gained traction in the capital market [7][10] - Huaxi Biological itself entered the recombinant collagen market in April 2022 by acquiring a 51% stake in Beijing Yierkang Biological Engineering for 233 million yuan [9] - The reports were published between 2022 and 2024, with the earliest being from August 2022 and the latest from February 2024 [8] Group 3: Regulatory and Compliance Issues - The article raised questions about the compliance and independence of the research reports, referencing the "Interim Regulations on the Release of Securities Research Reports" which mandates objectivity and fairness [10][11] - There were indications that some brokerages had deleted the criticized reports from the WIND platform, although they remained accessible on other platforms like Choice [5][11] - The production process of research reports involves ensuring data legality and undergoing compliance checks before publication, highlighting the importance of rigorous standards in the industry [11]

Core Viewpoint - The ongoing debate between hyaluronic acid and recombinant collagen in the capital market highlights the challenges faced by companies like Huaxi Biological, which is experiencing a decline in revenue and net profit after reaching a peak in 2022 [2][6]. Group 1: Company Response and Market Dynamics - Huaxi Biological criticized the recent reports from several securities firms that favor recombinant collagen over hyaluronic acid, claiming these reports misrepresent the safety and efficacy of hyaluronic acid [3][4]. - The company emphasized the importance of a healthy industry ecosystem, stating that without it, no company can achieve long-term success or maintain competitive advantages [5][6]. - Huaxi Biological is undergoing a comprehensive management transformation in 2024, including business process restructuring and digitalization, to address the challenges in the current operating environment [2][6]. Group 2: Financial Performance - In 2024, Huaxi Biological reported a revenue of 5.371 billion yuan, a year-on-year decrease of 11.61%, and a net profit of 174 million yuan, down 70.59% [6]. - The skin science innovation business, which accounts for nearly half of the company's revenue, saw a significant decline of 31.62% in revenue, totaling 2.569 billion yuan [6]. - In contrast, the medical terminal business achieved a revenue of 1.44 billion yuan in 2024, marking a growth of 32.03% [7]. Group 3: Industry Trends and Competition - The medical aesthetics industry is witnessing a shift from hyaluronic acid to recombinant collagen and other regenerative products, driven by evolving consumer preferences and technological advancements [5][9]. - The market for recombinant collagen is growing rapidly, with companies like Jinbo Biological and Giant Bio achieving substantial revenue increases in 2024, indicating a competitive landscape with low market concentration [8][9]. - Huaxi Biological is also investing in recombinant collagen research and development, aiming to leverage synthetic biology for technological upgrades and high-quality applications [7][8].

Core Viewpoint - The article discusses the conflict between Huaxi Biological and several securities firms regarding the comparison of hyaluronic acid and recombinant collagen protein, with Huaxi asserting that the notion of hyaluronic acid being outdated is a misleading narrative driven by "restless capital" [2][11]. Summary by Sections Company Background - Huaxi Biological, once a darling of the capital market, saw its stock peak at 313.1 yuan and market capitalization exceed 150 billion yuan, but has since experienced a significant decline, with its stock price dropping to 52.61 yuan and market cap to 25.3 billion yuan as of May 21 [3][12]. Market Dynamics - The rise of recombinant collagen protein companies like Juzhi Biological and Jinbo Biological has shifted capital focus, with these companies achieving record highs in stock prices [4][14]. - Huaxi Biological's performance has been declining, particularly in its functional skincare segment, while the recombinant collagen protein sector is experiencing rapid growth [4][20]. Securities Firms' Reports - Huaxi Biological criticized reports from nine securities firms that favor recombinant collagen over hyaluronic acid, claiming these reports mislead the market [6][9]. - Specific reports from Huatai Securities, Guojin Securities, and others highlighted the advantages of recombinant collagen, such as its biological features and safety, which Huaxi disputes [7][8]. Industry Trends - The market for recombinant collagen products in China is projected to grow at a compound annual growth rate of 44.93%, reaching 58.57 billion yuan by 2025 [12]. - Huaxi Biological's sales of hyaluronic acid accounted for 44% of the global market in 2021, but its revenue has been declining due to challenges in its functional skincare business [12][17]. Financial Performance - Huaxi Biological's revenue and net profit have been declining, with 2023 revenue at 6.08 billion yuan and a net profit of 593 million yuan, reflecting a year-on-year decrease of 4.45% and 38.97%, respectively [17][18]. - The company's functional skincare revenue peaked in 2022 but has since dropped, leading to overall performance issues [17][19]. Strategic Response - In response to declining performance, Huaxi Biological is restructuring its management and focusing on core competencies, including a shift in branding and operational strategies [19][20]. - The company has also made acquisitions to enter the collagen market, although its recent acquisition has not yet proven profitable [20]. Competitive Landscape - The article notes that both hyaluronic acid and recombinant collagen have their respective advantages, with hyaluronic acid still holding a competitive edge in certain applications despite market challenges [21].

Core Viewpoint - The article discusses the conflict between Huaxi Biological and several brokerage firms regarding the comparison of hyaluronic acid and recombinant collagen protein, with Huaxi asserting that the notion of hyaluronic acid being outdated is a misleading narrative driven by "restless capital" [1][9]. Group 1: Company Performance - Huaxi Biological's stock price peaked at 313.1 yuan with a market value exceeding 150 billion yuan, but as of May 21, it has plummeted to 52.61 yuan, with a market value of only 25.3 billion yuan, representing a loss of over 120 billion yuan in market capitalization [2][10]. - The company's revenue for 2023 and 2024 was 6.076 billion yuan and 5.371 billion yuan, respectively, showing a year-on-year decline of 4.45% and 11.61% [14]. - The net profit attributable to shareholders for the same years was 593 million yuan and 174 million yuan, reflecting a significant decline of 38.97% and 70.59% [14]. Group 2: Market Dynamics - The market is witnessing a shift in focus from hyaluronic acid to recombinant collagen protein, with companies like Juzhi Biological and Jinbo Biological experiencing significant stock price increases and strong revenue growth [12][17]. - The recombinant collagen protein market in China is projected to grow at a compound annual growth rate of 44.93%, reaching 58.57 billion yuan by 2025 [9]. Group 3: Industry Comparison - Huaxi Biological argues that the claims made by brokerage reports regarding the superiority of recombinant collagen protein over hyaluronic acid are misleading and lack scientific backing [5][18]. - Both hyaluronic acid and recombinant collagen protein have their respective advantages in different applications, with hyaluronic acid still holding competitive strength due to its established market presence [18]. Group 4: Company Strategy - In response to declining performance, Huaxi Biological is restructuring its management and focusing on core competencies, including a renewed emphasis on its strengths in hyaluronic acid [16]. - The company has also made strategic acquisitions, such as a 51% stake in Beijing Yierkang Biological Engineering, to enter the animal-derived collagen protein market, although this subsidiary reported losses in 2024 [17].

Summary of Key Points from the Conference Call Industry Overview - The new consumption brands are concentrated in traditional sectors such as personal care, household cleaning, and gold jewelry, which generally exhibit moderate growth. However, these brands demonstrate strong alpha characteristics, achieving high growth under weak beta effects [1][2][3] - The current economic environment has shifted consumer preferences towards products and services that meet basic needs, favoring new consumption brands that address pain points and provide emotional or practical value [4][5] Core Insights and Arguments - The current wave of "new quality consumption" is characterized by rapid revenue growth alongside profitability, driven by product positioning upgrades that enhance quality, emotional value, or address consumer pain points [2][5][8] - Traditional sectors like personal care and gold jewelry still have significant growth potential, particularly as e-commerce penetration rates increase. Companies that transition from traditional distribution logic to product-driven strategies are more likely to succeed [6][7] - New consumption companies such as Pop Mart and Miniso have shown performance that significantly exceeds market expectations, leading to valuation premiums due to their strong growth and scarcity in the market [9][10] Market Trends and Consumer Behavior - The current economic environment has not shown significant improvement, leading consumers to prefer products that fulfill basic needs. This trend suggests that new consumption brands may continue to perform well if the economic situation remains unchanged [4][11] - There is a notable shift in consumer behavior, with a greater emphasis on product quality and value for money, moving away from blind pursuit of high brand premiums. Companies must focus on product upgrades to meet these evolving consumer demands [10][12] Unique Characteristics of New Quality Consumption - New quality consumption brands are not new entrants but established companies with strong consumer recognition, often with over 20 years of history [5][10] - These brands leverage e-commerce, internet, and content marketing to achieve rapid market penetration while maintaining profitability, unlike many companies in the previous consumption wave that operated at a loss [5][8] Investment Implications - The current market environment favors companies with strong growth potential and scarcity, as these firms are more likely to attract investor interest. Their performance and valuation dynamics are expected to continue to support stock prices [11][21] - The competitive landscape in traditional sectors is tightening, allowing companies like Dengkang Oral Care to rapidly gain market share through innovative products and effective e-commerce strategies [17][23] Noteworthy Companies and Performance - In the beauty sector, brands like Perfect Diary and domestic brands are showing strong growth, while traditional international brands are losing market share [19][24] - In the gold jewelry sector, companies such as Chaohongji and Mankalon are experiencing robust growth by integrating emotional value into their products, leading to a shift in their valuation models [26] Conclusion - The new consumption trend is expected to persist, with a focus on individual company performance rather than broad sector recovery. Companies with established brands and innovative product offerings are likely to see continued success in the evolving market landscape [15][21][16]

Core Viewpoint - Huaxi Biological (688363.SZ) criticizes certain brokerage reports for misleading the market regarding the hyaluronic acid (HA) industry, claiming that these reports promote the idea that HA is outdated and misrepresent its value compared to recombinant collagen [1][2][5] Group 1: Criticism of Brokerage Reports - Huaxi Biological specifically names brokerages such as Western Securities, Anxin Securities, and Xinda Securities, accusing them of publishing misleading conclusions that favor recombinant collagen over hyaluronic acid [1][2][4] - The company argues that these reports distort scientific facts and mislead consumers, damaging the trust in the Chinese biotechnology and medical aesthetics industry [1][6] - Huaxi Biological emphasizes the importance of maintaining a fair competitive environment and the integrity of scientific information in the industry [1][6] Group 2: Market Dynamics and Competition - The criticism from Huaxi Biological is seen as a response to the rising competition from Juzhi Biological (02367.HK), which focuses on recombinant collagen and has been gaining market traction [1][8][12] - Huaxi Biological's performance has been declining, with projected revenues and net profits for 2024 showing significant decreases compared to previous years, while Juzhi Biological has experienced substantial growth [10][12] - The company highlights that the narrative of HA being outdated is a construct of "restless capital" aiming to shift focus to new market trends, which undermines the established value of HA [13][14] Group 3: Industry Support and Response - Following Huaxi Biological's statements, two industry associations, the China Fragrance and Cosmetic Industry Association and the China Aesthetic Medicine Association, issued a joint initiative advocating for scientific integrity and ethical marketing practices [7] - Huaxi Biological reports that many institutions have retracted erroneous reports and some have issued apologies, indicating a recognition of the misleading nature of the previous analyses [6][12] - The company maintains ongoing communication with brokerage firms regarding the accuracy of research reports and their implications for the industry [6][12]